William Blair analyst Sami Corwin reiterated a Market Perform rating on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments "Stock thoughts and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE